BioPharma Dive November 4, 2025
The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by simultaneously homing in on “unique pairs” of cancer targets.
Dive Brief:
- Neok Bio emerged from stealth on Tuesday with $75 million in Series A funding and plans to develop what it claims are “differentiated” antibody-drug conjugates, or ADCs, that can overcome the limitations of their predecessors.
- The company aims to develop a pipeline of “bispecific” ADCs that can simultaneously home in on what it says are “unique pairs” of cancer targets. One, codenamed Neok001, aims at B7-H3 and ROR1, two well-studied proteins involved in tumor growth. Another, Neok002, locks onto cells expressing EGFR and MUC1, two other known targets. Neok said...
Today's Sponsors
Today's Sponsor